-$3.01 Earnings Per Share Expected for Beigene Ltd (BGNE) This Quarter
Equities research analysts expect Beigene Ltd (NASDAQ:BGNE) to report earnings of ($3.01) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Beigene’s earnings, with estimates ranging from ($3.20) to ($2.87). Beigene posted earnings of $2.54 per share during the same quarter last year, which indicates a negative year over year growth rate of 218.5%. The firm is expected to report its next earnings report on Monday, November 12th.
On average, analysts expect that Beigene will report full year earnings of ($10.82) per share for the current year, with EPS estimates ranging from ($11.50) to ($9.87). For the next year, analysts expect that the company will post earnings of ($11.53) per share, with EPS estimates ranging from ($13.61) to ($8.23). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that that provide coverage for Beigene.
Beigene (NASDAQ:BGNE) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($2.92) EPS for the quarter, missing the Zacks’ consensus estimate of ($2.12) by ($0.80). The business had revenue of $52.80 million for the quarter, compared to the consensus estimate of $22.53 million. Beigene had a negative net margin of 75.19% and a negative return on equity of 24.14%. The business’s revenue for the quarter was up 5279999900.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.52) EPS.
BGNE traded up $0.64 during mid-day trading on Friday, reaching $172.67. 160,000 shares of the stock were exchanged, compared to its average volume of 336,551. The company has a debt-to-equity ratio of 0.16, a current ratio of 8.14 and a quick ratio of 8.10. The company has a market capitalization of $9.11 billion, a price-to-earnings ratio of -77.49 and a beta of 0.59. Beigene has a 1 year low of $77.54 and a 1 year high of $220.10.
In related news, Director Bros. Advisors Lp Baker purchased 5,814,100 shares of the business’s stock in a transaction that occurred on Thursday, August 2nd. The shares were bought at an average cost of $108.00 per share, with a total value of $627,922,800.00. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO John Oyler sold 2,550 shares of the business’s stock in a transaction dated Monday, July 16th. The stock was sold at an average price of $164.12, for a total transaction of $418,506.00. The disclosure for this sale can be found here. Insiders sold a total of 16,679 shares of company stock worth $2,808,018 over the last three months. 14.10% of the stock is owned by insiders.
Several large investors have recently modified their holdings of BGNE. Tower Research Capital LLC TRC boosted its holdings in shares of Beigene by 5,558.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 679 shares of the company’s stock worth $104,000 after buying an additional 667 shares during the last quarter. Rockefeller Capital Management L.P. purchased a new position in shares of Beigene in the 2nd quarter worth about $135,000. Virtu Financial LLC purchased a new position in shares of Beigene in the 2nd quarter worth about $212,000. Quantbot Technologies LP purchased a new position in shares of Beigene in the 1st quarter worth about $290,000. Finally, Northern Trust Corp purchased a new position in shares of Beigene in the 1st quarter worth about $302,000. 77.87% of the stock is currently owned by institutional investors.
Beigene Company Profile
BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Featured Story: Calculate Your Return on Investment (ROI)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.